CGEM Earnings — Cullinan Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
CGEM — Cullinan Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$16.44
Market Cap$1.0B
P/E—
52W Range$5.68 – $16.74
Next Earnings2026-08-06
About Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.